Aytu BioPharma, Inc. (AYTU)
USD 1.0
(-3.68%)
USD 1.0
(-3.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -5.25 Million USD | 69.21% |
| 2023 | -17.06 Million USD | -145.86% |
| 2022 | 37.21 Million USD | 197.32% |
| 2021 | -38.24 Million USD | -82.66% |
| 2020 | -20.93 Million USD | -24.27% |
| 2019 | -16.84 Million USD | 14.49% |
| 2018 | -19.7 Million USD | 2.11% |
| 2017 | -20.12 Million USD | 7.28% |
| 2016 | -21.7 Million USD | -184.37% |
| 2015 | -7.63 Million USD | -20.25% |
| 2014 | -6.34 Million USD | -12009.04% |
| 2013 | -52.41 Thousand USD | 6.99% |
| 2012 | -56.35 Thousand USD | 57.82% |
| 2011 | -133.61 Thousand USD | -135.49% |
| 2010 | -56.74 Thousand USD | -1.65% |
| 2009 | -55.82 Thousand USD | -1.52% |
| 2008 | -54.98 Thousand USD | -17.26% |
| 2007 | -46.89 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.46 Million USD | -204.23% |
| 2024 Q1 | -1.5 Million USD | -989.94% |
| 2024 Q4 | -3.65 Million USD | -48.13% |
| 2024 Q2 | 2.36 Million USD | 257.18% |
| 2023 Q4 | 169 Thousand USD | 101.82% |
| 2023 Q3 | -9.29 Million USD | -121.61% |
| 2023 FY | -17.06 Million USD | -145.86% |
| 2023 Q1 | -1.52 Million USD | -156.36% |
| 2023 Q2 | -4.19 Million USD | -174.95% |
| 2022 Q3 | 34.1 Million USD | 401.97% |
| 2022 Q4 | 2.7 Million USD | -92.07% |
| 2022 FY | 37.21 Million USD | 197.32% |
| 2022 Q2 | -11.29 Million USD | 59.23% |
| 2022 Q1 | -27.69 Million USD | -15.07% |
| 2021 Q1 | -3.55 Million USD | 46.39% |
| 2021 Q4 | -24.07 Million USD | 6.21% |
| 2021 Q2 | -5.57 Million USD | -56.75% |
| 2021 Q3 | -25.66 Million USD | -360.36% |
| 2021 FY | -38.24 Million USD | -82.66% |
| 2020 Q4 | -6.63 Million USD | -38.41% |
| 2020 FY | -20.93 Million USD | -24.27% |
| 2020 Q3 | -4.79 Million USD | 3.5% |
| 2020 Q1 | -4.73 Million USD | -3.39% |
| 2020 Q2 | -4.96 Million USD | -4.89% |
| 2019 Q2 | -4.55 Million USD | -33.17% |
| 2019 Q1 | -3.41 Million USD | 10.67% |
| 2019 Q4 | -4.57 Million USD | -6.55% |
| 2019 FY | -16.84 Million USD | 14.49% |
| 2019 Q3 | -4.29 Million USD | 5.54% |
| 2018 Q1 | -4.35 Million USD | -213.42% |
| 2018 FY | -19.7 Million USD | 2.11% |
| 2018 Q4 | -3.82 Million USD | 49.16% |
| 2018 Q3 | -7.52 Million USD | -88.4% |
| 2018 Q2 | -3.99 Million USD | 8.31% |
| 2017 Q3 | -4.85 Million USD | -15.75% |
| 2017 Q2 | -4.19 Million USD | 29.63% |
| 2017 Q4 | -1.38 Million USD | 71.4% |
| 2017 FY | -20.12 Million USD | 7.28% |
| 2017 Q1 | -5.96 Million USD | 55.14% |
| 2016 Q3 | -3.22 Million USD | -7.08% |
| 2016 Q4 | -13.29 Million USD | -312.1% |
| 2016 Q1 | -2.16 Million USD | -0.54% |
| 2016 Q2 | -3.01 Million USD | -39.34% |
| 2016 FY | -21.7 Million USD | -184.37% |
| 2015 Q1 | -10.79 Thousand USD | 3.06% |
| 2015 Q4 | -2.15 Million USD | -22784.27% |
| 2015 Q3 | -9401.00 USD | 38.52% |
| 2015 Q2 | -15.29 Thousand USD | -41.7% |
| 2015 FY | -7.63 Million USD | -20.25% |
| 2014 Q1 | -9073.00 USD | 24.13% |
| 2014 Q2 | -15 Thousand USD | -65.4% |
| 2014 Q4 | -11.13 Thousand USD | 45.85% |
| 2014 Q3 | -20.55 Thousand USD | -37.0% |
| 2014 FY | -6.34 Million USD | -12009.04% |
| 2013 Q2 | -18.83 Thousand USD | -9.68% |
| 2013 FY | -52.41 Thousand USD | 6.99% |
| 2013 Q4 | -11.95 Thousand USD | 4.72% |
| 2013 Q3 | -12.55 Thousand USD | 33.36% |
| 2013 Q1 | -17.17 Thousand USD | -54.9% |
| 2012 FY | -56.35 Thousand USD | 57.82% |
| 2012 Q4 | -11.08 Thousand USD | -20.19% |
| 2012 Q3 | -9223.00 USD | 51.14% |
| 2012 Q2 | -18.87 Thousand USD | 73.31% |
| 2012 Q1 | -70.73 Thousand USD | -253.3% |
| 2011 Q3 | -26.31 Thousand USD | -58.98% |
| 2011 Q2 | -16.55 Thousand USD | -26.2% |
| 2011 Q4 | -20.02 Thousand USD | 23.91% |
| 2011 Q1 | -13.11 Thousand USD | 5.09% |
| 2011 FY | -133.61 Thousand USD | -135.49% |
| 2010 FY | -56.74 Thousand USD | -1.65% |
| 2010 Q1 | -10.41 Thousand USD | -18.78% |
| 2010 Q2 | -18.47 Thousand USD | -77.39% |
| 2010 Q3 | -11.33 Thousand USD | 38.66% |
| 2010 Q4 | -13.81 Thousand USD | -21.93% |
| 2009 Q4 | -8768.00 USD | 42.05% |
| 2009 Q3 | -15.13 Thousand USD | 29.65% |
| 2009 Q2 | -21.5 Thousand USD | -82.26% |
| 2009 Q1 | -11.8 Thousand USD | 31.86% |
| 2009 FY | -55.82 Thousand USD | -1.52% |
| 2008 Q4 | -17.31 Thousand USD | -63.06% |
| 2008 Q3 | -10.62 Thousand USD | 30.32% |
| 2008 Q2 | -15.24 Thousand USD | -36.26% |
| 2008 Q1 | -11.18 Thousand USD | 18.58% |
| 2008 FY | -54.98 Thousand USD | -17.26% |
| 2007 Q4 | -13.74 Thousand USD | 8.14% |
| 2007 FY | -46.89 Thousand USD | 0.0% |
| 2007 Q3 | -14.95 Thousand USD | -113.46% |
| 2007 Q2 | -7007.00 USD | 0.0% |
| 2006 Q4 | -1905.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 103.147% |
| Embecta Corp. | 221.5 Million USD | 102.372% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 111.186% |
| Dynavax Technologies Corporation | -37.02 Million USD | 85.811% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.623% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 105.993% |
| PainReform Ltd. | -9.58 Million USD | 45.179% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 65.21% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -9.795% |
| SCYNEXIS, Inc. | 72.66 Million USD | 107.23% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -108.889% |
| Cosmos Health Inc. | -21.83 Million USD | 75.934% |
| Journey Medical Corporation | -2.07 Million USD | -153.449% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -9.795% |
| Safety Shot Inc | -12.18 Million USD | 56.878% |
| Alpha Teknova, Inc. | -35.56 Million USD | 85.226% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 96.703% |
| Bright Green Corporation | -8.89 Million USD | 40.909% |
| Procaps Group, S.A. | 38.97 Million USD | 113.481% |
| Theratechnologies Inc. | -10.62 Million USD | 50.56% |
| Harrow Health, Inc. | 580 Thousand USD | 1005.862% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -11.763% |
| Biofrontera Inc. | -22.67 Million USD | 76.831% |
| DURECT Corporation | -36.88 Million USD | 85.755% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 0.285% |
| Cronos Group Inc. | -81.37 Million USD | 93.544% |
| OptiNose, Inc. | -22.74 Million USD | 76.903% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.513% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 86.581% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 141.593% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 141.948% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -21.163% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 15.406% |
| Radius Health, Inc. | -3.92 Million USD | -33.86% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -48.975% |
| ProPhase Labs, Inc. | -21.61 Million USD | 75.691% |
| Phibro Animal Health Corporation | 53.31 Million USD | 109.855% |
| Procaps Group S.A. | 52.32 Million USD | 110.041% |
| Alvotech | -354.86 Million USD | 98.519% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 38.355% |
| Viatris Inc. | 766.2 Million USD | 100.686% |
| Rockwell Medical, Inc. | -6.67 Million USD | 21.229% |
| SIGA Technologies, Inc. | 83.62 Million USD | 106.283% |
| Tilray Brands, Inc. | -174.74 Million USD | 96.993% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 156.307% |
| Shineco, Inc. | -17.06 Million USD | 69.213% |
| PetIQ, Inc. | 60.01 Million USD | 108.754% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -10.92% |
| Incannex Healthcare Limited | -30.04 Million USD | 82.511% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.094% |
| Alimera Sciences, Inc. | -1.47 Million USD | -257.172% |
| Silver Spike Investment Corp. | 7.34 Million USD | 171.579% |
| Assertio Holdings, Inc. | -243.53 Million USD | 97.843% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 10.834% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 61.417% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 66.308% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 73.796% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 96.189% |
| Hempacco Co., Inc. | -8.81 Million USD | 40.379% |
| Talphera, Inc. | -16.88 Million USD | 68.891% |
| Alvotech | -354.86 Million USD | 98.519% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 109.829% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.441% |
| Currenc Group, Inc. | -6.64 Million USD | 20.942% |
| Kamada Ltd. | 10.06 Million USD | 152.206% |
| Indivior PLC | -4 Million USD | -31.35% |
| Evoke Pharma, Inc. | -7.43 Million USD | 29.295% |
| Flora Growth Corp. | -50.35 Million USD | 89.566% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 73.796% |
| Evolus, Inc. | -49.23 Million USD | 89.328% |
| HUTCHMED (China) Limited | 18.37 Million USD | 128.593% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.667% |
| Akanda Corp. | -10.05 Million USD | 47.729% |